Antiplatelet treatment in patients with end stage renal disease (ESRD) on hemodialysis (HD)
is still challenging because of bleeding and thrombotic complications. The investigators
hypothesized ticagrelor once daily dose would achieve tolerable antiplatelet effects compared
with ticagrelor twice a day dose in ESRD patients on HD.